3. Spinal muscular atrophy Clinical trials / Disease details


Clinical trials : 217 Drugs : 149 - (DrugBank : 33) / Drug target genes : 54 - Drug target pathways : 80

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003474-31-DK
(EUCTR)
02/11/2021Safety and efficacy of Intrathecal OAV101 in Pediatric Patients with Spinal Muscular Atrophy (SMA) (STEER)A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are = 2 to < 18 years of age, treatment naive, sitting, and never ambulatory - STEER Spinal Muscular Atrophy
MedDRA version: 20.1;Level: PT;Classification code 10041582;Term: Spinal muscular atrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Zolgensma
Product Name: OAV101
Product Code: OAV101
INN or Proposed INN: ONASEMNOGENE ABEPARVOVEC
Other descriptive name: previously termed sc.AAV9.CB.SMN and AVXS-101
Trade Name: Okrido 6mg/mL oral solution
Product Name: Okrido
INN or Proposed INN: prednisolone sodium phosphate
Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE
Novartis Pharma AGNULLNAFemale: yes
Male: yes
125Phase 3United States;United Arab Emirates;Saudi Arabia;Taiwan;Thailand;Russian Federation;Colombia;Italy;Vietnam;India;Egypt;Mexico;Brazil;Malaysia;Singapore;Denmark;South Africa;China